Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Afaq Sarwar who wrote (2727)	1/15/1998 6:01:00 PM
From: don roberson	Read Replies (2) \| Respond to of 3906

Afaq: Great idea. maybe I can get Dan to go with me. Once they move in, I'll make the trip. Perhaps a few samples will be obtained. Then we'll have a "personal experience" write up. Maybe I can do a little study. Like the response time with the Goofey Suit on, and with it off.

To: Afaq Sarwar who wrote (2727)	1/15/1998 11:07:00 PM
From: Hal	Read Replies (3) \| Respond to of 3906

Harvard Scientific Funding by Top Executives January 15, 1998 9:20 PM EST RENO, Nev.--(BUSINESS WIRE)--Jan. 15, 1998--Harvard Scientific Corp., (OTC Bul Bd: HVSF) a Nevada corporation, announced that in view of several requests for further information concerning the announcement earlier today of funding by the company's top two executives and members of its board of directors, Thomas E. Waite, president and CEO, and Jackie R. See, M.D., F.A.C.C., director of research, Waite confirmed that he and Dr. See would personally fund the company with an initial equity purchase of at least $500,000 and an option to increase the funding to an aggregate of ten million dollars during 1998. Terms of the financing agreement call for the funding to be completed in tranches of $500-thousand to two million dollars in exchange for equity in the company. The initial tranche of funding and subsequent tranches aggregating up to the first five million dollars are calculated at a rate consistent with the average and un-discounted closing bid price of the common shares over the ten day trading period ended Jan. 12, 1998, the most recent period available before the agreement was signed by the parties on Jan. 13, 1998. That price is $0.3164 per share. The next $2.5 million will be calculated at 200 percent of the initial tranche acquisition price, or $0.6324 per share. The remaining $2.5 million will be calculated at 400 percent of the initial tranche acquisition price, or $1.265 per share. The initial tranche will be made forthwith upon the effectiveness of a registration statement to be filed covering the issuable shares. Funding of all tranches subsequent to the initial tranche is at the option of Dr. See and Waite. Waite stated, however, that, based on present circumstances, Dr. See and he had every intention of completing the financing. Waite added, "the funding will be strategically executed as needed and will enable the company to move forward in a manner that is both prudent and in the best interest of its shareholders." An independent review as to the fairness of the agreement will be issued by a member firm of the New York Stock Exchange. In addition, the funding arrangement will be submitted to the shareholders of the company for approval. Harvard Scientific Corp. is a biopharmaceutical company that develops products relating to liposomal delivery of Prostaglandin E-1 for the treatment of male erectile dysfunction, impotency and sexual enhancement. The company's patented process allows the Prostaglandin E-1 to be administered as a liquid via a painless delivery system. The company also has developed a topically applied skin treatment for psoriasis and is working with the FDA to establish Phase I clinical trials protocol for that product. Prostaglandin E-1 is a naturally occurring vasodilator originally approved by the U.S. FDA for intravenous infusion in neonates. In 1995, PGE-1 was approved by the FDA as a treatment for male erectile dysfunction for Upjohn's Caverject(R), which is administered by needle injection. In November 1996, Vivus, Inc.'s MUSE(R) delivery system was approved by the FDA. The company believes that its product represents a tremendous treatment advantage over other delivery systems currently being utilized in the industry. From time to time the company may issue forward looking statements which involve risks and uncertainties. This statement may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results could differ and any forward looking statements should be considered accordingly. c Business Wire. All rights reserved. Hal